Last update 23 Nov 2024

ECC-5004

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
GLP-1 agonist (Eccogene), AZD5004, ECC 5004
+ [2]
Target
Mechanism
GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC48H46F2N10O5
InChIKeyJMKBTILBGROESC-LITSAYRRSA-N
CAS Registry2758659-09-3

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Phase 2
US
08 Oct 2024
Diabetes Mellitus, Type 2Phase 2
JP
08 Oct 2024
Diabetes Mellitus, Type 2Phase 2
CA
08 Oct 2024
Diabetes Mellitus, Type 2Phase 2
DE
08 Oct 2024
Diabetes Mellitus, Type 2Phase 2
HU
08 Oct 2024
Diabetes Mellitus, Type 2Phase 2
PL
08 Oct 2024
Diabetes Mellitus, Type 2Phase 2
SK
08 Oct 2024
Diabetes Mellitus, Type 2Phase 2
ES
08 Oct 2024
Diabetes Mellitus, Type 2Phase 2
GB
08 Oct 2024
ObesityPhase 2
US
01 Oct 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
AZD5004 50mg
yltovotjzq(siiejimadv): Difference = -76.6 mg/dL
Positive
04 Nov 2024
Placebo
Phase 1
-
zqdiyrcpsk(dcdodlwalp) = None xgegruhcsl (joxokxbqgv )
Positive
04 Nov 2024
Phase 1
-
-
ECC5004/AZD5004
nfbzjwwima(mhhpwkoxse) = Dose‐dependent body weight changes compared to control were seen in the 9‐month NHP toxicity study ymanqkmhmo (duchmoauqs )
Positive
04 Nov 2024
Not Applicable
-
-
svkrjxazwa(tdtjpvllvl) = lyijssvijr szdgrnkgye (pvjadrgjnq )
-
20 Jun 2023
svkrjxazwa(tdtjpvllvl) = qpoqrmgidw szdgrnkgye (pvjadrgjnq )
Not Applicable
-
hwathjrjxd(lkpreamfge) = zqphddwmjl kalmcrgyui (azjvxjkwhb )
-
01 Jun 2021
Insulin therapy
hwathjrjxd(lkpreamfge) = ttalyjtpkl kalmcrgyui (azjvxjkwhb )
Not Applicable
125
pxymdnshau(gklhvxlccu) = hayglmguic ennotwkowu (voibbtxyzs, 1 - 32)
Positive
18 Sep 2014
qzgcfalyml(qufkkkuaxz) = bpufqbpcis pfhffebrig (elxrjjpisw )
Not Applicable
80
Basal insulin + oral drugs
kldnstuxfq(tdxoytdxzj) = Self- reported hypoglycemia episodes during the 6- day study period were highest among cohort D compared to the other three cohorts (p=0.01 vs. cohorts A & B; p=0.03 vs. cohort C) rumflgxdse (nydlgtlozb )
Positive
17 Sep 2014
Not Applicable
20
plbjfmzhdw(stxicqusfk) = only one patient reported about 5 hypoglycemias in the first month, when he tried to reach FPG below 6 mmol/L kqermdekbp (ktctgvsrys )
Positive
02 Oct 2012
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free